Costs and effectiveness of staging and treatment options in early-stage Hodgkin's disease

International Journal of Radiation Oncology Biology Physics

Volumn 50, Issue 4, 2001, Pages 979-989

  Ng, Andrea K ^a   Kuntz, Karen M ^c   Mauch, Peter M ^a   Weeks, Jane C ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cost effectiveness analysis; Costs; Hodgkin's disease; Patient preferences; Utilities

Indexed keywords

COSTS; RADIOTHERAPY; SIMULATION;

HODGKIN'S DISEASES; MARKOV MODELS;

ONCOLOGY;

ARTICLE; CANCER STAGING; CANCER THERAPY; COST; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; HODGKIN DISEASE; LAPAROTOMY; LIFE EXPECTANCY; MORBIDITY; PATIENT ATTITUDE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HODGKIN DISEASE; HUMANS; LAPAROTOMY; NEOPLASM STAGING; QUALITY-ADJUSTED LIFE YEARS; RADIOTHERAPY; SENSITIVITY AND SPECIFICITY;

EID: 0035879443     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01546-2     Document Type: Article

References (65)

1. Toward comprehensive management tailored to prognostic factors of patients with clinical stages of I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials; 1964-1987
2. The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease
3. Limited radiation therapy for selected patients with pathological stages IA and IIA Hodgkin's disease
4. Recent advances in the treatment of Hodgkin's disease
5. Management of early-stage Hodgkin's disease; A continuing evolution
6. The optimal dose of radiation in Hodgkin's disease; An analysis of clinical and treatment factors affecting in-field disease control
7. Treatment of early-stage Hodgkin's disease
8. Hodgkin's disease-new treatment strategies toward the cure of patients
9. EBVD combination chemotherapy plus low dose involved field radiation is a highly effective treatment modality for early stage Hodgkin's disease
10. Laparotomy versus no laparotomy in the management of early-stage, favorable prognosis Hodgkin's disease; A decision analysis
11. Decision analysis on alternative treatment strategies for favorable-prognosis, early-stage Hodgkin's disease
12. Markov models in medical decision making; A practical guide
13. Recommendations of the panel of cost-effectiveness in health and medicine
14. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care
15. Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies; Results from the University of Nebraska 1987-1991
16. Second cancer after the treatment for Hodgkin's disease; A report from the International Database on Hodgkin's Disease
17. Second solid tumors and leukemia after treatment for Hodgkin's disease; An analysis of 1126 patients from a single institution
18. Second malignancies after childhood Hodgkin's disease. The Memorial Sloan-Kettering Cancer Center experience
19. Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation; Relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy
20. Long-term survival in Hodgkin's disease
21. Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin's disease
22. Prognostic factors for positive surgical staging in patients with Hodgkin's disease
23. Staging laparotomy with splenectomy from Hodgkin's disease; The Stanford experience
24. Morbidity of staging laparotomy in Hodgkin's disease
25. Complications from staging laparotomy for Hodgkin's disease
26. Stage IA and IIA supradiagphragmatic Hodgkin's disease; Prognostic factors in surgically-staged patients treated with mantle-paraaortc irradiation
27. A randomised study of adjuvant MVPP chemotherapy after mantle radiotherapy in pathologically staged IA-IIB Hodgkin's disease; 10-year follow-up
28. Radiotherapy versus combined modality therapy of stages I and II Hodgkin's disease
29. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease; 7-year results of a prospective randomized trial
30. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathological stage I-IIA Hodgkin's disease; 8-year update of an Italian prospective randomized study
31. Vinblastine, bleomycin, methotrexate; An effective adjuvant in favorable Hodgkin's disease
32. Improved survival in patients with limited stage IIIA Hodgkin's disease treated with combined radiation therapy and chemotherapy
33. Stage III Hodgkin's disease; Improved survival with combined modality therapy as compared with radiation therapy alone
34. Impact of adjuvant radiation in the patterns and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations
35. Long-term complications of treatment and causes of mortality after Hodgkin's disease
36. Risk of second cancer after treatment for Hodgkin's disease
37. Second cancer risk following Hodgkin's disease; A 20-year follow-up study
38. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease
39. Wide-field radiation therapy with or without chemotherapy for patients with Hodgkin's disease in relapse after initial combination chemotherapy
40. Radiation therapy salvage of Hodgkin's disease following chemotherapy failure
41. Radiation therapy salvage of Hodgkin's disease following chemotherapy failure
42. Salvage radiotherapy in recurrent Hodgkin's disease
43. Radiotherapy with curative intent; An option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease
44. Salvage radiotherapy for Hodgkin's disease following chemotherapy failure
45. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
46. Allogeneic, synergistic, and autologous marrow transplantation for Hodgkin's disease; The 21-year Seattle experience
47. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV+/-P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy
48. High-dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease
49. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients
50. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease; Results of a BNLI randomised trial
51. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease; Importance of disease status at transplant
52. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease
53. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease; Analysis of the Stanford University results and prognostic indices
54. Cardiac disease following treatment of Hodgkin's disease
55. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease